Last reviewed · How we verify
Bepreve
At a glance
| Generic name | Bepreve |
|---|---|
| Also known as | bepotastine besilate |
| Sponsor | North Texas Institute for Clinical Trials |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Allergic conjunctivitis
Common side effects
- Mild taste following instillation
- Eye irritation
- Headache
- Nasopharyngitis
Serious adverse events
- Hypersensitivity reactions (itching, body rash, swelling of lips/tongue/throat)
Key clinical trials
- A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (PHASE3)
- The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (PHASE3)
- A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (PHASE3)
- A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (PHASE3)
- Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (PHASE1)
- Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis (PHASE4)
- Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment (PHASE4)
- Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bepreve CI brief — competitive landscape report
- Bepreve updates RSS · CI watch RSS
- North Texas Institute for Clinical Trials portfolio CI